CD274 and non-small cell lung carcinoma: Hence, our study focuses on the retrospective assessment of patients with NSCLC and low PD-L1 expression (<50%) being treated either with upfront chemo-immunotherapy combination (pembrolizumab plus platinum salt plus pemetrexed) versus chemotherapy alone (platinum-based doublet chemotherapy) followed by second-line immunotherapy upon disease recurrence.